<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078257</url>
  </required_header>
  <id_info>
    <org_study_id>005</org_study_id>
    <nct_id>NCT03078257</nct_id>
  </id_info>
  <brief_title>Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients</brief_title>
  <acronym>DPABIAP</acronym>
  <official_title>Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiplatelet treatment is important for coronary artery disease(CAD) patients .Some patients
      are resistant to antiplatelet treatment based on platelet function tests(PFT).Currently the
      results of PFT are mainly based on the analysis of peripheral blood. instead, adverse
      cardiovascular events in CAD patients may be more directly related to platelet activities in
      the coronary arteries. There's no evidence of system study to prove the PFT of peripheral
      blood can represent the platelet functions in coronary arteries.The purpose of this study is
      to determine the different platelet activities in the blood of peripheral vein (PV),
      peripheral artery (PA), intracoronary artery (IC) in the CAD patients without or with
      different interventions.

      our study is divided into three parts: Part A: To study the different platelet activities in
      the blood of PV, PA, IC in the CAD patients with dual antiplatelet therapy.

      Part B: To explore the different platelet activities of the above three sites in ST-segment
      elevation myocardial infarction (STEMI) patients who are administrated platelet membrane
      glycoprotein Ⅱb/Ⅲa (GPⅡb/Ⅲa) receptor antagonist ( tirofiban ) in PV or IC and dual
      antiplatelet therapy.

      Part C: To explore the different platelet activities of the above three sites in STEMI
      patients who are administrated antiplatelet thrombolysin or placebo in PV and dual
      antiplatelet therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A:A total of 30 CAD patients are recruited.All patients are on loading dose of 300 mg
      clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days and a loading dose
      of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days. All
      patients plan to receive coronary arteriography (CAG) or percutaneous coronary intervention
      (PCI).The investigators sample blood from PV,PA and IC before PCI.Regional differences will
      be compared between blood samples from PV,PA and IC by light aggregometry (agonists:
      arachidonic acid, LTA-AA; adenosine diphosphat, LTA-ADP), VerifyNow P2Y12 assays. Differences
      between LTA and VerifyNow P2Y12-assay will also be compared.

      Part B:A total of 30 STEMI patients are recruited.Patients are randomly assigned to 2
      groups.A group(n=15) is given tirofiban through PV, the other group(n=15) is given through
      IC.All patients are on loading dose of 600 mg clopidogrel and 300 mg aspirin.All patients
      plan to receive emergency PCI. Group PV: a loading dose of 10ug/kg tirofiban is given in 3
      min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.Group IC: a loading
      dose of 10ug/kg tirofiban is given through IC,followed by a maintenance dose of 0.15ug/kg*min
      for 48h. Blood samples are collceted from PV, PA and IC before the injection of loading dose
      tirofiban , and 15min after the injection.Regional differences will be compared between blood
      samples from PV,PA and IC by LTA-AA; LTA-ADP, LTA-RIS(agonists:ristocetin),VerifyNow P2Y12
      assays.

      Part C:A total of 30 STEMI patients are recruited.Patients are randomly assigned to 2
      groups.A group(n=15) is given antiplatelet thrombolysin(the frist antiplatelet drugs based on
      GP Ib receptor which completed the preclinical and phase I clinical studies,and already has
      entered phase II clinical studies) through PV, the other group(n=15) is given placebo through
      PV.All patients are on loading dose of 600 mg clopidogrel and 300 mg aspirin.All patients
      plan to receive emergency PCI.Both Groups are given in the same way , a loading dose of 5
      IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h. Blood
      samples are collceted from PV, PA and IC before the injection of loading dose of antiplatelet
      thrombolysin or placebo, and 15 min after the injection.Regional differences will be compared
      between blood samples from PV,PA and IC by LTA-AA; LTA-ADP, LTA-RIS and VerifyNow P2Y12
      assays.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet aggregation</measure>
    <time_frame>2 hours</time_frame>
    <description>Regional differences between blood samples from PV,PA and IC by LTA and VerifyNow P2Y12 assays.The results of LTA are reported in platelet aggregation rate（%）.Platelet aggregation was induced using 0.5 mg/ml arachidonic acid (AA) and 5 μmol/l ADP.The maximum aggregation achieved during an 8-minute period was used for analysis.The results of the VerifyNow P2Y12-assay are reported in P2Y12 reaction units (PRU).(using 20 μmol/l ADP as the agonist and 22 nmol/l prostag- landin E1 (PGE1). a value that uses iso- thrombin receptor-activating peptide to approximate a baseline off-drug platelet reactivity value, and percentage inhibition.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>dual antiplatelet therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel +aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tirofiban in PV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel +aspirin + tirofiban in PV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tirofiban in IC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel +aspirin +tirofiban in IC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antiplatelet thrombolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clopidogrel +aspirin +antiplatelet thrombolysin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>clopidogrel +aspirin +placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tirofiban in PV</intervention_name>
    <description>a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.
(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day.</description>
    <arm_group_label>tirofiban in PV</arm_group_label>
    <other_name>GPⅡb/Ⅲa receptor antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tirofiban in IC</intervention_name>
    <description>a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg*min for 48h.
(clopidogrel 600 mg+ ASA 300 mg)x1 day.</description>
    <arm_group_label>tirofiban in IC</arm_group_label>
    <other_name>GP IIb/IIIa receptor antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiplatelet thrombolysin</intervention_name>
    <description>a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.
(clopidogrel 600 mg+ ASA 300 mg)x1 day.</description>
    <arm_group_label>antiplatelet thrombolysin</arm_group_label>
    <other_name>GP Ib receptor antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.
(clopidogrel 600 mg+ ASA 300 mg)x1 day.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days</description>
    <arm_group_label>dual antiplatelet therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.</description>
    <arm_group_label>dual antiplatelet therapy</arm_group_label>
    <arm_group_label>tirofiban in PV</arm_group_label>
    <arm_group_label>tirofiban in IC</arm_group_label>
    <arm_group_label>antiplatelet thrombolysin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days</description>
    <arm_group_label>tirofiban in PV</arm_group_label>
    <arm_group_label>tirofiban in IC</arm_group_label>
    <arm_group_label>antiplatelet thrombolysin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CAD patients plan to receive coronary arteriography (CAG) or percutaneous coronary
             intervention (PCI).

          2. Patient aged &gt;18 years and ≦75 years old;

          3. Signed inform consent

        Exclusion Criteria:

          1. Allergy or intolerance to ASA, clopidogrel , tirofiban ,antiplatelet thrombolysin;

          2. Subjects at a high risk of bleeding (e.g. platelet count&lt; 100*109/L, known bleeding
             diathesis , active peptic ulcer );

          3. Patients who are planning to take warfarin or drugs that potentially could interfere
             with the anti-platelet effects .

          4. severe hemodynamic instability

          5. severe liver and renal dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuming Zhang, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chai, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dingguo Zhang, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Platelet Activities</keyword>
  <keyword>light aggregometry</keyword>
  <keyword>VerifyNow P2Y12-assay</keyword>
  <keyword>peripheral vein</keyword>
  <keyword>peripheral artery</keyword>
  <keyword>intracoronary artery</keyword>
  <keyword>tirofiban</keyword>
  <keyword>antiplatelet thrombolysin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Tirofiban</mesh_term>
    <mesh_term>Fibrinolysin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

